- In a recent announcement Clifford A. Hudis of MSKCC will become the President of the American Society of Clinical Oncology (ASCO).
- Lloyd Old, a researcher and former administrator of two cancer research institutes, passed away the week of December 2.
- Researchers from MSKCC, Weill Cornell, and the National Cancer Institute developed a new method that reveals complete set of aberrant signaling pathways that give rise to cancers.
- Dr. Behfar Ehdaie of MSKCC is the lead author of a study that shows Hormone-targeted therapy for prostate cancer may raise the risk of potentially dangerous blood clots.
Author Archives: Mark
MSKCC in the News: November 15 – November 28
- Monica Morrow, Chief of MSKCC’s Breast Service in the Department of Surgery, is the lead author of a study published in The Lancet that shows that MRI screening does not lead to improved outcomes for most women with breast cancer who undergo imaging prior to selecting a treatment.
- Nature reports that researchers at MSKCC have identified a previously unknown mechanism of resistance to the newly approved melanoma drug, vemurafenib, an oral targeted therapy used to treat advanced melanoma whose tumors contain a mutation in a gene called BRAF.
MSKCC in the News: October 31 – November 14
- New research, published in Nature, conducted by a group of scientists led by Dr. Lorenz Studer of MSKCC showed that the transformation of the stem cells into neuron cells which produced the chemical dopamine not only survived but helped to slow the progression of Parkinson’s in monkeys.
- The Business Wire reported that the New York Genome Center will launch what will become one of the largest genomic facilities in North America, establishing an unprecedented, large-scale collaborative venture in genomic medicine that will include MSKCC and 10 other leading medical/research institutions.